Trial Profile
A Phase Ib Safety and Immunogenicity Clinical Trial of Heterologous Prime-boost Immunisation With ChAd3-EBO Z and MVA-EBO Z in Healthy Senegalese Adult Volunteers Aged 18-50 Years
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Feb 2019
Price :
$35
*
At a glance
- Drugs GSK 3390107A (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions
- 08 Nov 2018 Results published in the Journal of Infectious Diseases
- 12 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.